Related Experiment Video

Updated: Apr 18, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Resistance to HER2-targeted therapies: a potential role for FOXM1

Bridgette F Peake1, Rita Nahta2

  • 1Molecular & Systems Pharmacology Program, Graduate Division of Biological and Biomedical Sciences, Emory University.

Breast Cancer Management
|January 20, 2015
PubMed

Insights

FOXM1 may drive resistance to trastuzumab in HER2-overexpressing breast cancer. Inhibiting FOXM1 could restore sensitivity to HER2-targeted therapies, offering a new treatment strategy for refractory cases.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Trastuzumab is effective for HER2-overexpressing metastatic breast cancer, but resistance is a clinical challenge.
  • Mechanisms of trastuzumab resistance are actively being investigated to improve patient outcomes.
  • Identifying novel therapeutic targets is crucial for overcoming treatment failure.

Purpose of the Study:

  • To review the evidence linking FOXM1 to trastuzumab resistance in breast cancer.
  • To explore FOXM1 as a potential therapeutic target in trastuzumab-refractory breast cancer.
  • To summarize pre-clinical findings on FOXM1's role in overcoming resistance.

Main Methods:

  • Review of existing scientific literature and pre-clinical data.
  • Analysis of breast cancer gene expression datasets.
  • Evaluation of studies investigating FOXM1's impact on HER2-targeted therapy sensitivity.

Main Results:

  • FOXM1 expression is elevated in breast cancer and may correlate with HER2 levels.
  • Overexpression of FOXM1 decreases sensitivity to trastuzumab and lapatinib.
  • Knockdown or inhibition of FOXM1 can reverse resistance to HER2-targeted therapies.

Conclusions:

  • FOXM1 is implicated as a mediator of trastuzumab resistance in HER2-positive breast cancer.
  • Targeting FOXM1 presents a promising strategy for overcoming resistance to HER2-targeted therapies.
  • Further pre-clinical investigation into FOXM1's role is warranted for clinical translation.
Keywords:
breast cancerfoxm1her2lapatinibresistancetrastuzumab

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.9K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K